Finnegan client Abbott Laboratories filed an infringement suit July 21 in the District of Delaware against Hospira Inc. related to their recent ANDA application seeking approval for three formulations of an injectable version of Abbott’s kidney disease treatment Zemplar®. Over the last year, Abbott has brought suit in the same court against Ben Venue Laboratories for an injectable version of the patented treatment, as well as Roxanne Laboratories and Sandoz Inc. over their generic versions of Zemplar® capsules. Finnegan represents Abbott in all of these matters.